Samantha Salvatora, PA
Physician Assistant · Houston, TXNPI 1144765256
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (36.4%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Syndax Pharmaceuticals, Inc. at 43.2% of the total. 2025 is the largest year on record at $23,182, more than ten times the $196 reported in 2021. Among physician assistant clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 293 payments — averaging $152.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Syndax Pharmaceuticals, Inc.$19K
- E.r. Squibb & Sons, L.L.C.$9K
- Bristol Myers Squibb$5K
- Incyte Corporation$3K
- Lilly USA, LLC$2K
- AbbVie$1K
- plus $5K from 25 others
What the payments were for
- Consulting fees$9,20321%
- Speaking & faculty fees$16,24036%
- Travel & lodging$8,19018%
- Food & beverage$10,54924%
- Education$4181%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Syndax Pharmaceuticals, Inc. | 29 | $19,250 |
| E.r. Squibb & Sons, L.L.C. | 19 | $9,126 |
| Bristol Myers Squibb | 54 | $4,855 |
| Incyte Corporation | 35 | $3,425 |
| Lilly USA, LLC | 12 | $1,873 |
| AbbVie | 20 | $1,312 |
| Astellas Pharma US Inc | 22 | $833 |
| CTI Biopharma Corp. | 3 | $752 |
| Novartis | 22 | $593 |
| Pfizer | 7 | $347 |
| Johnson & Johnson | 9 | $287 |
| AstraZeneca | 9 | $259 |
| Adaptive Biotechnologies Corporation | 7 | $229 |
| Pharmaessentia USA Corporation | 8 | $216 |
| Medtronic | 1 | $169 |
| Sobi, Inc | 5 | $135 |
| Beigene USA, Inc. | 5 | $130 |
| Genentech, Inc. | 1 | $116 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $96 |
| Daiichi Sankyo Inc. | 3 | $83 |
| Geron Corporation | 2 | $72 |
| GSK | 3 | $67 |
| Rigel Pharmaceuticals, Inc. | 2 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $56 |
| Amgen | 2 | $55 |
| Azurity Pharmaceuticals, Inc. | 3 | $53 |
| Servier Pharmaceuticals LLC | 2 | $50 |
| Taiho Oncology, Inc. | 1 | $29 |
| Blueprint Medicines Corporation | 1 | $26 |
| Merck | 1 | $26 |
| Invivyd Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$44,600 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BosulifBosutinib | 41 | $550,195 |
| IdhifaEnasidenib Mesylate | 16 | $519,242 |
| ImbruvicaIbrutinib | 24 | $355,901 |
| JakafiRuxolitinib Phosphate | 27 | $354,995 |
| SprycelDasatinib | 34 | $285,339 |
| VenclextaVenetoclax | 25 | $230,007 |
| InqoviDecitabine/Cedazuridine | 18 | $142,664 |
| Posaconazole | 32 | $45,713 |
| Voriconazole | 14 | $3,970 |
| Cefpodoxime Proxetil | 18 | $3,431 |
| ValacyclovirValacyclovir Hcl | 112 | $2,837 |
| Levofloxacin | 62 | $1,547 |
| Imatinib Mesylate | 12 | $1,060 |
| Potassium Chloride | 30 | $850 |
| Hydroxyurea | 21 | $551 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerBosulif | $347 | $550,19541 claims |
| Bristol Myers SquibbIdhifa | $4,855 | $519,24216 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $96 | $355,90124 claims |
| Incyte CorporationJakafi | $3,425 | $354,99527 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $9,126 | $285,33934 claims |
| AbbVieVenclexta | $1,312 | $230,00725 claims |
| Taiho Oncology, Inc.Inqovi | $29 | $142,66418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.
Other physician assistant in Houston
- Simone SteeleHouston$237K
- Amanda WilhiteHouston$207K
- Christina YazdaniHouston$72K
- Julie Huynh-LuHouston$64K
- Jennifer FalconeHouston$48K
- Jacqueline WeatherlyHouston$47K
- Virginia SchneiderHouston$43K
- Jill MillerHouston$32K
- Mercedes SerranoHouston$28K
- Cynthia TrickettDallas$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.